(Q37449898)

20 August 2017

0 references

1 reference

title

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention (English)

1 reference

20 August 2017

0 references

1 reference

Pierre Amarenco

1

1 reference

20 August 2017

Julien Labreuche

series ordinal

2

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

453-463

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Stroke prevention, blood cholesterol, and statins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

The dynamics of statins: from event prevention to neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

The paradox of cholesterol and stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Lipid lowering and recurrent stroke: another stroke paradox?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Nonfasting triglycerides and risk of ischemic stroke in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Rosuvastatin in older patients with systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Autopsy prevalence of coronary atherosclerosis in patients with fatal stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970058-4

7 January 2021

10.1016/S1474-4422(09)70058-4

Identifiers

DOI

1 reference

20 August 2017

1 reference